Compare Citius Pharmaceuticals Inc (CTXR) vs Sirius XM Holdings Inc (SIRI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs Sirius XM Holdings Inc — how do they compare? Citius Pharmaceuticals Inc trades at $0.53 (market cap $14.64M), while Sirius XM Holdings Inc trades at $30.93 (market cap $10.23B). The key difference: Sirius XM Holdings Inc is far larger — about 698.8× Citius Pharmaceuticals Inc's market cap, and Sirius XM Holdings Inc pays a 3.55% dividend while Citius Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| CTXR | SIRI | |
|---|---|---|
Market Cap | $14.64M | $10.23B |
Sector | Health | Media |
52-Week High | $1.82 | $30.75 |
52-Week Low | $0.53 | $19.92 |
Enterprise Value | $10.86M | $19.90B |
Dividend Yield | — | 3.55% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTXR trades at $0.54, down 7.33% in the last session, with a bearish technical signal from moving averages. The company reported a net loss of $37.43M for 2025 and has missed earnings expectations for the last three quarters. Recent news highlights progress with LYMPHIR, including Phase 1 data presentations at ASCO and international expansion, alongside $5.6M in net revenue for the first half of 2026.
Despite a high analyst buy consensus (83%), CTXR faces significant fundamental challenges with negative profitability and cash burn. Investment opportunity hinges on successful commercialization of LYMPHIR, but risks include ongoing losses, dilution from recent financing, and clinical execution uncertainties. The stock remains speculative with high risk-reward dynamics.
Sirius XM Holdings (SIRI) trades at $30.67, up 0.82% with strong technical momentum and bullish moving average signals. The company shows improved fundamentals with three consecutive quarterly earnings beats and a return to profitability in 2025 after a challenging 2024. Recent developments include a strategic advertising partnership with YouTube and potential merger discussions with iHeartMedia, driving positive investor sentiment.
The outlook remains positive with analysts maintaining a $31.17 consensus target and 58% buy ratings. Key opportunities include revenue diversification through new partnerships and strong cash flow generation supporting dividends and buybacks. Risks include intense media competition and high debt levels despite recent improvement from 94% to 36% debt-to-asset ratio since 2022.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About Sirius XM Holdings Inc
SiriusXM Holdings is now composed of two businesses: SiriusXM and Pandora. SiriusXM transmits music, talk shows, sports, and news via its two satellite radio networks, primarily to consumers in vehicles who pay a subscription fee. The firm's radios come preinstalled on a wide range of light vehicles in the U.S. and Canada. The firm acquired Pandora Media in February 2019 via an all-stock transaction. Pandora is a streaming music platform that offers an ad-supported radio option and a paid on-demand service. Liberty Media owns 80% of SiriusXM, traded through its Liberty SiriusXM Group tracking stock.
Read more on SIRI →
